Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Nephrology and Critical Care Medicine
• Anticoagulation Therapy

Background:

• Continuous renal replacement therapy (CRRT) is crucial for critically ill patients with kidney failure.
• Edoxaban is a direct oral anticoagulant with limited data on its use in CRRT.
• Understanding edoxaban's behavior during CRRT is essential for safe and effective anticoagulation.

Purpose of the Study:

• To evaluate edoxaban clearance during in vitro CRRT.
• To assess edoxaban protein binding and circuit adsorption.
• To provide initial dosing recommendations for edoxaban in CRRT patients.

Main Methods:

• In vitro experiments using continuous veno-venous hemofiltration (CVVH) and hemodialysis (CVVHD) modes.
• Quantification of edoxaban and urea concentrations using liquid chromatography-tandem mass spectrometry.
• Pharmacokinetic analysis and multivariate models to assess clearance factors.

Main Results:

• Edoxaban clearance was mainly through hemofilter adsorption (74% with HF1400, 65% with M150).
• Mean protein binding was 41%, with no significant influence of CRRT mode, filter type, or dilution on clearance.
• Doses of 30-45 mg daily were estimated to achieve target exposure across various effluent flow rates.

Conclusions:

• A daily dose of 45 mg edoxaban is predicted to achieve therapeutic systemic exposure in CRRT patients.
• This dosing strategy requires further clinical investigation for safety and efficacy.
• Edoxaban's pharmacokinetic profile during CRRT is predictable based on effluent flow rate.